Environmental aspects have always been dealt with sensitively within APL. All our properties, units, products and services impact on the environment in some way, and we have chosen to focus on the most important aspects.

We work towards constant improvements and a sustainable company. This means that we are constantly reviewing our processes to minimise waste of resources. The result is less environmental impact, efficient processes, better finances, a better customer offering and a contribution to society for sustainable development.

The Global Goals and the 2030 Agenda for Sustainable development

APL has joined the 17 UN Global Goals and the Agenda 2030 for Sustainable development.

Based on the owner's expectations of APL as a state-owned company, our mission, our connection to, for example, the UN Global Compact and Fossil Free Sweden, as well as our stakeholders' expectations and ambitions, APL has chosen to prioritize six of the goals:

  • Good health and well-being (Goal 3)
  • Clean water and sanitation (Goal 6)
  • Affordable and clean energy (Goal 7)
  • Decent work and economic growth (Goal 8)
  • Responsible consuption and production (Goal 12)
  • Climate action (Goal 13)

Based on these, we have formulated four long-term goals for long-term sustainable growth and profitability, with the aim of 2030:

  1. Develop and provide a quality assured and medically purposeful range of individualized extemporaneous drugs (Goal 3)
  2. Create growth with increased productivity as well as being an attractive employer that continually further develops our employees' skills in an equal environment that promotes diversity (Goal 8)
  3. Reduce the use of fossil energy sources and logistics services and minimize resource use and emissions in our production (Goals 12, 13)
  4. Actively ensure that employees and suppliers comply with the APL Ethical Guidelines and Code of Conduct and actively protect human rights with zero tolerance against corruption and bribery (Goals 8)


Work to reduce waste

Our goal is to reduce the overall amount of waste, including medical waste and to increase the proportion of waste being recycled. This contributes to Sweden’s environmental goals through

  • reduced emissions of carbon dioxide when fossil components are burnt (limited climate impact)
  • reduced creation of hazardous waste and risk of polluting land and groundwater when waste is stored and processed (poison-free environment)
  • reduced creation of waste (good developed environment).

In this way, we also contribute to UN’s goals for sustainable consumption and production (Goal 12).

Interventions to reduce energy consumption

APL is one of the actors in the Fossil Free Sweden initiative, and we have taken powerful charge of our own energy consumption to reduce carbon dioxide emissions. For example, we have initiated a detailed energy mapping of the company and installed separate meters to facilitate follow-up of our energy consumption.


Extemporeläkemedel och lagerberedningar

Beställ online via EbEx


Telefon: 010-447 97 00
e-post: kundservice@apl.se


Ordinarie öppettider:
Helgfria vardagar 08:00-17:00



Reservrutinen används endast för akuta medicinskt viktiga beställningar av extemporeläkemedel under tiden EbEx ordersystem inte kan nås. För att kunna använda dig av rutinen så krävs det att du redan är befintlig kund hos APL och har ett kundnummer.

Beställningar görs på för ändamålet avsedd blankett och får inte innehålla några patientuppgifter.

Beställningen skickas via e-post till kundservice@apl.se.



Visiting adress:

Prismavägen 2, Kungens Kurva

+46 10 447 96 00

Other contact information

About APL

Apotek Produktion & Laboratorier (APL) is one of Europe’s leading companies manufacturing extemporaneous drugs and stock preparations. We have a social mission from the Swedish government, but also work together with other pharmaceutical companies to create the greatest possible patient benefit. Our vision is that we will make a difference for patients with special needs. We are also an established contract manufacturer within Life Science in Scandinavia, where we deliver services within development and analysis. With more than 500 employees and five manufacturing units in Malmö, Gothenburg, Stockholm and Umeå, we develop drugs that improve and save lives.

Read more